Bolt Biotherapeutics Q3 EPS $(0.43) Beats $(0.50) Estimate, Sales $2.53M Beat $1.72M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bolt Biotherapeutics reported Q3 losses of $(0.43) per share, beating the analyst consensus estimate of $(0.50) by 14%. This is a 25.86% increase over losses from the same period last year. The company also reported quarterly sales of $2.53 million, beating the analyst consensus estimate of $1.72 million by 46.98%. This is a 19.70% increase over sales from the same period last year.
November 09, 2023 | 10:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bolt Biotherapeutics reported better than expected Q3 earnings and sales, which could positively impact the stock in the short term.
Bolt Biotherapeutics reported Q3 earnings and sales that beat analyst estimates. This is generally seen as positive news and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100